Assessment of Quality of Life in Chinese Patients with Gastroenteropancreatic Neuroendocrine Tumors Abstract #2177

Introduction: Descriptive analysis on the QOL in patients(pts) with GEP-NET are rare.
Aim(s): To assess the QOL in Chinese pts with GEP-NET and analysis the influencing factors.
Materials and methods: This was a cross-sectional study and data were obtained using the questionnaire designed by ourselves according to EORTC QLQ-C30 and GI NET21 CHINESE MANDARIN. All pts completed survey at baseline and 3 months later.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Huang-Ying Tan

To read results and conclusion, please login ...

Further abstracts you may be interested in

#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Sara Massironi
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#36 A monocentric analysis of patients with pulmonary neuroendocrine tumors over 15 years: long term survival and life quality dependent from histological subtypes and surgical management
Introduction: Pulmonary neuroendocrine tumors substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized interdisciplinary centers, a broad therapeutical armentarium can be used to achieve optimal treatment.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Johannes N Hoffmann
Authors: Zahn S, Hornung H, Schick K S, Winter H, ...
#39 Specialist dietetic input and nutritional outcomes in Neuroendocrine Tumour Patients
Introduction: Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that are complex to manage and require a multidisciplinary approach. The most common primary sites are the small intestine and pancreas. The disease itself, as well as sequelae from surgery and medical therapy, can have a negative impact on patients’ nutritional status. Weight loss is known to be a poor prognostic indicator.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MRS CALEY L SCHNAID
Authors: Schnaid C, Khan M, Davies P, Jamieson A, ...
#40 Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients
Introduction: Neuroendocrine tumors (NETs) are rare neoplasms, heterogeneous, and with variable biological behavior. NETs can be sporadic or they can arise in complex endocrine hereditary syndromes such as Multiple Endocrine Neoplasias (MEN), Familial Paragangliomatosis (FPGL), Neurofibromatosis type 1 (NF1), von Hippel-Lindau Disease (VHL), Tuberous Sclerosis (TSC) and Carney Complex (CC). By performing genetic screening, patients with hereditary NETs can be identified before the development of tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Antongiulio Faggiano